Periodontal disease and diabetes mellitus: a two-way relationship.
Severe periodontal disease often coexists with severe diabetes mellitus. Diabetes is a risk factor for severe periodontal disease. A model is presented whereby severe periodontal disease increases the severity of diabetes mellitus and complicates metabolic control. We propose that an infection-mediated upregulation cycle of cytokine synthesis and secretion by chronic stimulus from lipopolysaccharide (LPS) and products of periodontopathic organisms may amplify the magnitude of the advanced glycation end product (AGE)-mediated cytokine response operative in diabetes mellitus. In this model, the combination of these 2 pathways, infection and AGE-mediated cytokine upregulation, helps explain the increase in tissue destruction seen in diabetic periodontitis, and how periodontal infection may complicate the severity of diabetes and the degree of metabolic control, resulting in a 2-way relationship between diabetes mellitus and periodontal disease/infection. This proposed dual pathway of tissue destruction suggests that control of chronic periodontal infection is essential for achieving long-term control of diabetes mellitus. Evidence is presented to support the hypothesis that elimination of periodontal infection by using systemic antibiotics improves metabolic control of diabetes, defined by reduction in glycated hemoglobin or reduction in insulin requirements.
Department of Oral Biology, School of Dental Medicine, State University of New York at Buffalo, USA. sara_grossi@sdm.buffalo.edu
S G
SG
Grossi
R J
RJ
Genco
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000378:metabolism; D016905:Gram-Negative Bacterial Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology*; D010510:Periodontal Diseases / Q000209:etiology* / Q000382:microbiology / Q000628:therapy*; D015854:Up-Regulation
D000900:Anti-Bacterial Agents; D016207:Cytokines; D017127:Glycation End Products, Advanced